April 17, 2024 07:22 AM EDTUpdated 10:52 AM
R&D

Lil­ly plans for Zep­bound la­bel ex­pan­sion in­to sleep ap­nea in mid-2024 on back of Phase 3 win

Katherine Lewin

News Reporter

Eli Lil­ly’s weight loss drug Zep­bound hit the pri­ma­ry end­points in two Phase 3 tri­als for adults with ob­struc­tive sleep ap­nea …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Is there room for MASH drugs in a GLP-1 world?

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

BioN­Tech says VEGF bis­pe­cif­ic’s PD-L1 tar­get, com­bo plans will be its edge

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times